Future treatment strategies for novel Middle East respiratory syndrome coronavirus infection

Zaki A.M., Van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N. Engl. J. Med, 367, 19, pp. 1814-1820, (2012)

Van Boheemen S., De Graaf M., Lauber C., Et al., Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans, MBio, 3, 6, (2012)

Raj V.S., Mou H., Smits S.L., Et al., Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC, Nature, 495, 7440, pp. 251-254, (2013)

Cyranoski D., Critics slam treatment for SARS as ineffective and perhaps dangerous, Nature, 423, 6935, (2003)

Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W., Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus, Lancet, 361, 9374, pp. 2045-2046, (2003)

Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W., Treatment of SARS with human interferons, Lancet, 362, 9380, pp. 293-294, (2003)

Falzarano D., De Wit E., Martellaro C., Callison J., Munster V.J., Feldmann H., Inhibition of novel beta coronavirus replication by a combination of interferon-a2b and ribavirin, Sci. Rep, 3, 1686, (2013)

Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M.-H., Albrecht J.K., Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial, Lancet, 358, 9286, pp. 958-965, (2001)

Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A., Walmsley S.L., Mazzulli T., Avendano M., Derkach P., Ephtimios I.E., Kitai I., Mederski B.D., Shadowitz S.B., Gold W.L., Hawryluck L.A., Rea E., Chenkin J.S., Cescon D.W., Poutanen S.M., Detsky A.S., Clinical Features and Short-term Outcomes of 144 Patients with SARS in the Greater Toronto Area, Journal of the American Medical Association, 289, 21, pp. 2801-2809, (2003)

Gierer S., Bertram S., Kaup F., Et al., The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies, J. Virol, 87, 10, pp. 5502-5511, (2013)

Zaki A.M., Van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N. Engl. J. Med, 367, 19, pp. 1814-1820, (2012)

Van Boheemen S., De Graaf M., Lauber C., Et al., Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans, MBio, 3, 6, (2012)

Raj V.S., Mou H., Smits S.L., Et al., Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC, Nature, 495, 7440, pp. 251-254, (2013)

Cyranoski D., Critics slam treatment for SARS as ineffective and perhaps dangerous, Nature, 423, 6935, (2003)

Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W., Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus, Lancet, 361, 9374, pp. 2045-2046, (2003)

Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W., Treatment of SARS with human interferons, Lancet, 362, 9380, pp. 293-294, (2003)

Falzarano D., De Wit E., Martellaro C., Callison J., Munster V.J., Feldmann H., Inhibition of novel beta coronavirus replication by a combination of interferon-a2b and ribavirin, Sci. Rep, 3, 1686, (2013)

Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M.-H., Albrecht J.K., Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial, Lancet, 358, 9286, pp. 958-965, (2001)

Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A., Walmsley S.L., Mazzulli T., Avendano M., Derkach P., Ephtimios I.E., Kitai I., Mederski B.D., Shadowitz S.B., Gold W.L., Hawryluck L.A., Rea E., Chenkin J.S., Cescon D.W., Poutanen S.M., Detsky A.S., Clinical Features and Short-term Outcomes of 144 Patients with SARS in the Greater Toronto Area, Journal of the American Medical Association, 289, 21, pp. 2801-2809, (2003)

Gierer S., Bertram S., Kaup F., Et al., The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies, J. Virol, 87, 10, pp. 5502-5511, (2013)